Aurobindo Pharma has received an approval for raising funds through issue of Equity / GDRs / ADRs / FCCBs or any other equity related instruments up to an amount of $600 million or rupee equivalent thereof subject to approval of the shareholders of the company and other necessary approvals.
The board of directors at their meeting held on November 06, 2015 has approved for the same. The board has also decided to seek approval of the shareholders through postal ballot for the above purpose.
Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
